Viva Biotech grants 8.58m share options to boost CDMO performance

Viva Biotech Holdings, a company listed on the Hong Kong Stock Exchange, has granted 8,580,000 share options to 44 employees, primarily core members of its CDMO operations. The options, granted on December 2, 2025, have an exercise price of HK$2.05 per share, reflecting the closing price on the grant date. This price is higher than the five-day average closing price of HK$1.96. The options will be valid and exercisable until March 30, 2031, subject to specific vesting conditions.

Vesting will occur in three tranches: 40% on March 31, 2028, 30% on March 31, 2029, and the final 30% on March 31, 2030. These vesting schedules are contingent on both individual performance targets and significant Group revenue growth. The Group's revenue for the 2027, 2028, and 2029 financial years must increase by no less than 35%, 55%, and 75% respectively, compared to the 2025 financial year.

Following this grant, the company retains 119,845,000 shares available for future grants under its Post-IPO Share Option Scheme. The Board has determined that a separate clawback mechanism is unnecessary due to existing provisions within the scheme that allow for the lapse and cancellation of options under various scenarios, safeguarding the company's interests.